Shares of NeuroOne Medical Technologies surged 8.3% to $1.79 on July 30, bucking a weak healthcare tape, after investors seized on positive physician feedback and seizure-reduction data from a Mayo Clinic epilepsy study involving the company's flagship brain ablation device. The bounce follows a rough stretch — the stock slid from $1.90 on July 24 — raising the question of whether clinical validation can outrun a ticking cash-burn clock.
Mayo Clinic's Backing Isn't New, but Fresh Data Still Moves the Needle
Mayo Clinic, based in Rochester, was an early collaborator on the technology, purchasing an 11% ownership stake and becoming NeuroOne's first investor.
The device is the first FDA-cleared system capable of simultaneously recording brain activity and performing radiofrequency ablation — essentially diagnosing and treating seizures in one step. CEO Dave Rosa has stated that in epilepsy procedures there have been "no reported procedural adverse events," with most patients reportedly seizure-free or showing significant seizure reduction. Positive real-world feedback from a top-tier institution adds credibility that could accelerate hospital adoption.
Revenue Is Growing Fast but From a Tiny Base
In Q2 fiscal 2026, NeuroOne posted product revenue of $2.4 million, up 72% year-over-year, with a 53.8% gross margin.
Full-year FY2026 guidance targets at least $10.5 million in sales, a 17% increase , with international expansion targeted for late 2026. But revenue remains modest for a public company, and a Q1 restatement tied to a revenue recognition error — overstating sales by roughly $0.5 million — dented credibility on financial controls.
The Cash Runway Is the Real Risk
Cash stood at just $3.6 million at December 31, 2025, down from $6.6 million the prior quarter, with operations consuming $3.1 million in a single quarter.
Management has acknowledged "substantial doubt" about the company's ability to continue as a going concern — accounting language meaning the money could run out. NeuroOne expanded an at-the-market equity offering in June 2026 , signaling likely dilution ahead. With roughly 8.7 million shares outstanding (post-reverse split) , the market cap hovers near just $15 million.
Expanding Beyond Epilepsy Could Help — If Funding Holds
A limited market release for facial pain (trigeminal neuralgia) treated 12 patients across three centers with a reported 100% success rate.
The company has also received FDA clearance for that indication. Broadening the device's uses is smart strategy, but each new launch requires capital this company may not have.
Bottom line: The clinical story is real and encouraging. The financial story — going-concern warnings, restatements, dilution — demands that investors weigh today's pop against the survival math ahead.